Search
Showing results for "aboriginal respiratory"
Four The Kids Research Institute Australia researchers – working across diverse fields including paediatric anaesthesia, bioinformatics, ear health, and the health impacts of biodiesel exhaust – have been named as finalists in the 2021 Premier’s Science Awards.
The Wesfarmers Centre is pleased to announce the successful applications for the 2016 Round 2 Wesfarmers Centre Seed Funding.
Are you listening? The inaugural OMOZ Workshop - towards a better understanding of otitis media
Peter Ruth Elke Richmond Thornton Seppanen MBBS MRCP(UK) FRACP PhD BSc PhD Head, Vaccine Trials Group Co-head, Bacterial Respiratory Infectious
Invasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.
Pneumonia is a leading cause of childhood mortality with Streptococcus pneumoniae a major contributor. Pneumococcal conjugate vaccines (PCVs) have been introduced into immunisation programs in many low- to middle-income countries yet there is a paucity of data evaluating the effectiveness in these settings. We assess the effectiveness of 13-valent PCV against hypoxic pneumonia, hospitalisation and other clinical endpoints in children <5 years living in Eastern Highlands Province, Papua New Guinea).
Christopher Deborah Blyth Lehmann MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases;
Pulmonary exacerbations pose a significant clinical burden on people with cystic fibrosis (pwCF). Whether management of exacerbations should change in the context of modulator therapy is unclear. We describe the characteristics, treatment and lung function outcomes of pulmonary exacerbations requiring intravenous antibiotic therapy (PERITs) in a contemporary Australian cohort of pwCF, in an era of rapidly broadening access to modulator therapy.
This manuscript will give a brief overview of clinical trial design including the strengths and limitations of various approaches
Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of